Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,302 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT07056556RecruitingPhase 1
Study of BL-M09D1 for advanced lung and other solid tumors
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06612840RecruitingPhase 1
A study of GNC-077 for advanced lung cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced non-small cell lung cancer or other solid tumors that have spread. It aims to see if the drug is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03778814RecruitingPhase 1
Personalized T-cell therapy for advanced lung or solid tumors
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
Guanzhou, GuangdongAges 18–75 - NCT05754853RecruitingPhase 3
MRG002 antibody compared with standard chemo for HER2 bladder cancer
This trial studies whether MRG002, a targeted antibody treatment, works better than the patient’s chosen standard chemotherapy. It is for people with HER2-positive advanced or metastatic urothelial (bladder/urinary tract) cancer whose disease has progressed after prior platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Birmingham, AlabamaAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06219941RecruitingPhase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
Orange, CaliforniaAges 18 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT06150365RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
BeijingAges 18–70 - NCT07593092RecruitingPhase 1
Testing new cancer immunotherapy for advanced ovarian cancer
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
Lake Success, New YorkAges 18 years+ - NCT07281326RecruitingPhase 1
A study of AK138D1 for advanced solid tumors
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
Harbin, HeilongjiangAges 18–75 - NCT07269080RecruitingPhase 1
Radiation plus immunotherapy for advanced solid tumors
This trial tests whether adding targeted radiation to your metastatic tumors can help your immunotherapy work better. It is for people with advanced solid tumors that have spread to 3-10 spots and who have been on immunotherapy for at least 3 months.
Chicago, IllinoisAges 18 years+ - NCT06796907RecruitingPhase 1/Phase 2
Mocertatug rezetecan with other drugs for advanced solid tumors
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
La Jolla, CaliforniaAges 18 years+ - NCT06759649RecruitingPhase 1
Study of COM503 for advanced solid tumors
This trial tests a new drug called COM503 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. It aims to see if the drug is safe and how well it works.
New Haven, ConnecticutAges 18 years+ - NCT06667960RecruitingPhase 1/Phase 2
Study of JK06 for advanced solid tumors
This trial tests a new drug called JK06 for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if JK06 is safe and effective.
AntwerpAges 18 years+ - NCT05904782Recruiting
Brief positive-activity coaching for caregivers of advanced cancer
This trial tests a short program meant to support caregivers’ positive feelings while they care for someone with stage IV cancer. If you’re eligible, you may be asked to complete study activities by phone or internet for a set period of time.
Houston, TexasAges 18 years+ - NCT05407844Enrolling by invitation
Community health worker program to improve palliative care
This study tests whether a community health worker can help people with advanced cancer get better palliative care support. Palliative care focuses on comfort, symptom relief, and support for patients and caregivers.
Birmingham, AlabamaAges 18 years+ - NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Sacramento, CaliforniaAges 18 years+ - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT07003022RecruitingPhase 2
Two-drug combo for advanced colorectal cancer
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Shanghai, ChinaAges 18–80 - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Duarte, CaliforniaAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,302 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.